[go: up one dir, main page]

ECSP17057848A - Composiciones farmacéuticas para terapia combinada - Google Patents

Composiciones farmacéuticas para terapia combinada

Info

Publication number
ECSP17057848A
ECSP17057848A ECIEPI201757848A ECPI201757848A ECSP17057848A EC SP17057848 A ECSP17057848 A EC SP17057848A EC IEPI201757848 A ECIEPI201757848 A EC IEPI201757848A EC PI201757848 A ECPI201757848 A EC PI201757848A EC SP17057848 A ECSP17057848 A EC SP17057848A
Authority
EC
Ecuador
Prior art keywords
combination
agonist
ppar
present
disease
Prior art date
Application number
ECIEPI201757848A
Other languages
English (en)
Inventor
Luciano Adorini
Mark Pruzanski
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17057848(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of ECSP17057848A publication Critical patent/ECSP17057848A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende una combinación de un agonista de FXR y por lo menos un agente reductor de lípidos (por ejemplo, un agonista de PPAR-alfa, agonista de PPAR-delta, agonista dual de PPAR-alfa y delta, y/o estatina). También se describe el uso de la combinación para el tratamiento o prevención de una enfermedad o afección mediada por FXR, tal como cirrosis biliar primaria (PBC), colangitis esclerosante primaria (PSC), hipertensión portal, diarrea por ácidos biliares, NAFLD (enfermedad de hígado graso no alcohólica), NASH (esteatohepatitis no inducida por alcohol), y otras enfermedades hepáticas crónicas. La combinación de la presente invención es útil para el tratamiento o prevención de afecciones relacionadas con niveles elevados de lípidos y enzimas hepáticas. La presente invención también se relaciona con envases o kits que incluyen la combinación farmacéutica.
ECIEPI201757848A 2015-02-06 2017-08-31 Composiciones farmacéuticas para terapia combinada ECSP17057848A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06

Publications (1)

Publication Number Publication Date
ECSP17057848A true ECSP17057848A (es) 2017-10-31

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201757848A ECSP17057848A (es) 2015-02-06 2017-08-31 Composiciones farmacéuticas para terapia combinada

Country Status (30)

Country Link
US (3) US11311557B2 (es)
EP (2) EP3253382B1 (es)
JP (2) JP7306791B2 (es)
KR (1) KR20170115071A (es)
CN (1) CN107405325B (es)
AR (1) AR103624A1 (es)
AU (2) AU2016215179B2 (es)
BR (1) BR112017016766B1 (es)
CA (1) CA2976056C (es)
CL (3) CL2017001983A1 (es)
CO (1) CO2017007959A2 (es)
CR (1) CR20170356A (es)
DK (1) DK3253382T3 (es)
EA (1) EA036404B1 (es)
EC (1) ECSP17057848A (es)
ES (1) ES2905872T3 (es)
GT (1) GT201700174A (es)
IL (2) IL253719B (es)
MA (1) MA40814A1 (es)
MX (1) MX388508B (es)
NI (1) NI201700100A (es)
PE (1) PE20180027A1 (es)
PH (1) PH12017501384A1 (es)
SG (1) SG11201706347SA (es)
SV (1) SV2017005512A (es)
TN (1) TN2017000344A1 (es)
TW (1) TW201628625A (es)
UA (1) UA125744C2 (es)
WO (1) WO2016127019A2 (es)
ZA (1) ZA201706007B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017016766B1 (pt) 2015-02-06 2023-11-07 Intercept Pharmaceuticals, Inc Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática
MX2017012893A (es) 2015-04-07 2018-01-15 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas.
US11072631B2 (en) 2015-09-24 2021-07-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
FI3435996T3 (fi) * 2016-03-31 2025-06-11 Genfit Elafibranori käytettäväksi primaarisen biliaarisen kolangiitin hoidossa
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
MX382537B (es) * 2017-02-21 2025-03-13 Genfit Combinacion de un agonista de ppar con un agonista de fxr
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
JP7631217B2 (ja) * 2019-04-10 2025-02-18 ジェンフィット 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法
AU2020284135A1 (en) * 2019-05-30 2022-01-06 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
KR20220035365A (ko) * 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
CA3154859A1 (en) * 2019-09-20 2021-03-25 Reneo Pharmaceuticals, Inc. Use of a ppar-delta agonist in the treatment of kidney disease
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
EP4583874A1 (en) * 2022-12-21 2025-07-16 Charles University, Faculty Of Pharmacy In Hradec Kralove Multitarget nuclear receptor ligands based on 2-(4-(quinolin-2-yloxy)phenoxy)propanoic acid and 2-(4-(quinoxalin-2-yloxy)phenoxy)propanoic acid for the treatment of metabolic and liver diseases

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (es) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FI52570C (fi) 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (es) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (es) 1973-07-05 1977-07-15 Roussel Uclaf
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP0607536B1 (en) 1992-12-08 2001-01-24 Ss Pharmaceutical Co., Ltd. Arylamide derivatives
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1998032444A1 (en) * 1997-01-24 1998-07-30 The Regents Of The University Of California USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION
CN1117566C (zh) * 1997-08-29 2003-08-13 辉瑞产品公司 包含氨氯地平和抑制素化合物的联合药物形式
RU2235094C2 (ru) 1997-10-27 2004-08-27 Др. Редди`З Лабораториз Лимитед Бета-арил-альфа-оксизамещенные алкилкарбоновые кислоты, способы их получения, промежуточные соединения, способы их получения, фармацевтическая композиция, способы лечения или предупреждения заболеваний на основе новых соединений
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
WO2000037057A2 (en) 1998-12-18 2000-06-29 Abbott Laboratories Novel formulations comprising lipid-regulating agents
EP1140079B1 (en) 1998-12-23 2009-06-03 Glaxo Group Limited Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US6071955A (en) 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
BR0110208A (pt) 2000-04-19 2003-01-28 Borody Thomas J Composições e terapias para distúrbios associados com hiperlipidemia
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US20040072868A1 (en) 2000-09-18 2004-04-15 Collins Jon Loren Substitued aminopropoxyaryl derivatives useful as agonists for lxr
CA2440680C (en) 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
GB0405349D0 (en) * 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
EP2712617B2 (en) 2004-03-12 2020-11-18 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using Fxr ligands
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
AU2007230989A1 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
JP5119241B2 (ja) 2006-05-24 2013-01-16 イーライ リリー アンド カンパニー Ｆｘｒアゴニスト
EA014720B1 (ru) 2006-05-24 2011-02-28 Эли Лилли Энд Компани Соединения и способы модуляции fxr
DK2040713T3 (da) 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
WO2008015763A1 (fr) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ES2681794T3 (es) * 2009-11-26 2018-09-17 Genfit Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
PT3336097T (pt) 2012-06-19 2020-10-29 Intercept Pharmaceuticals Inc Preparação da forma não cristalina de ácido obeticólico
JP6272888B2 (ja) 2012-10-26 2018-01-31 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体を調製するためのプロセス
ME03082B (me) 2013-05-14 2019-01-20 Intercept Pharmaceuticals Inc 11-hidroksil-6-supsтituisani-derivati žučnih kiselina i njihovi aminoкiselinski konjugati као modulatori receptora za farnezoid х
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
BR112017016766B1 (pt) 2015-02-06 2023-11-07 Intercept Pharmaceuticals, Inc Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática
AU2020284135A1 (en) 2019-05-30 2022-01-06 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease

Also Published As

Publication number Publication date
JP2022000483A (ja) 2022-01-04
US12337003B2 (en) 2025-06-24
US20220280533A1 (en) 2022-09-08
IL290823A (en) 2022-04-01
AU2021201015A1 (en) 2021-03-11
US20220280534A1 (en) 2022-09-08
DK3253382T3 (da) 2022-02-14
IL253719B (en) 2022-04-01
WO2016127019A3 (en) 2016-11-03
CN107405325B (zh) 2021-11-12
GT201700174A (es) 2018-11-13
ES2905872T3 (es) 2022-04-12
EP4035665A1 (en) 2022-08-03
JP7306791B2 (ja) 2023-07-11
EA201791770A1 (ru) 2017-12-29
CA2976056A1 (en) 2016-08-11
BR112017016766A2 (pt) 2018-04-10
ZA201706007B (en) 2019-01-30
CL2017001983A1 (es) 2018-04-20
WO2016127019A2 (en) 2016-08-11
UA125744C2 (uk) 2022-06-01
SG11201706347SA (en) 2017-09-28
NI201700100A (es) 2018-09-06
KR20170115071A (ko) 2017-10-16
PE20180027A1 (es) 2018-01-09
EP3253382A4 (en) 2018-10-31
TN2017000344A1 (en) 2019-01-16
IL253719A0 (en) 2017-09-28
PH12017501384A1 (en) 2018-01-08
CO2017007959A2 (es) 2017-10-31
CL2018003604A1 (es) 2019-02-22
CA2976056C (en) 2024-02-06
SV2017005512A (es) 2018-06-12
US20180008616A1 (en) 2018-01-11
BR112017016766B1 (pt) 2023-11-07
TW201628625A (zh) 2016-08-16
MA40814A1 (fr) 2019-08-30
EP3253382A2 (en) 2017-12-13
CR20170356A (es) 2018-02-28
CN107405325A (zh) 2017-11-28
JP2018504438A (ja) 2018-02-15
EA036404B1 (ru) 2020-11-06
AR103624A1 (es) 2017-05-24
HK1246191A1 (zh) 2018-09-07
EP3253382B1 (en) 2021-11-17
MX388508B (es) 2025-03-20
MX2017010131A (es) 2017-11-01
CL2018001006A1 (es) 2018-06-15
US11311557B2 (en) 2022-04-26
AU2016215179B2 (en) 2021-02-25
AU2016215179A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
ECSP17057848A (es) Composiciones farmacéuticas para terapia combinada
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
MX2019011795A (es) Composicion dirigida al gen s1pr4 para prevenir o tratar la esteatohepatitis no alcoholica.
BR112018007857A2 (pt) combinações de gemcabene para o tratamento de doença cardiovascular
CL2012001124A1 (es) Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl.
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
EA201592020A1 (ru) Новая композиция для неалкогольной жировой болезни печени (нажбп)
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2021014585A (es) Composiciones farmaceuticas que comprenden un agonista de fxr y un fibrato para usarse en el tratamiento de la enfermedad hepatica colestatica.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
BR112013019394A2 (pt) uso de um agente
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
CL2013001910A1 (es) Compuestos derivados de fenil-isoxazol; metodo para prepararlos; composicion farmaceutica que los comprende; combinacion que los comprende junto a otro agente terapeutico o preventivo de infecciones virales; metodo para prevenir o tratar infecciones virales; y su uso para el tratamiento de infecciones virales.
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
MX2019014677A (es) Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas.
BR102020012866A8 (pt) Composições tópicas contendo derivados de n-acil-dipeptídeo e ácido glicólico
BR112017028185A2 (pt) composições farmacêuticas sólidas para tratar hcv
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
WO2009075838A3 (en) Treatment of menorrhagia with aromatase inhibitor
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)